复发/难治性多发性骨髓瘤患者接受T细胞重定向免疫治疗中完全缓解与可测量残留病的临床意义
该研究在201例接受CAR-T细胞或T细胞衔接器(TCE)临床试验的复发/难治性多发性骨髓瘤患者中,用二代流式分析可测量残留病(MRD)动态。达到10⁻⁶ MRD阴性使进展和/或死亡风险降低89%,持续MRD阴性者生存优于短暂MRD阴性者,持续MRD阳性者生存极差。多因素分析中仅完全缓解(CR)和MRD状态对无进展生存和总生存有独立预后价值。
要点
- 达到10⁻⁶ MRD阴性使进展和/或死亡风险降低89%。
- 持续MRD阴性者生存优于短暂MRD阴性者,持续MRD阳性者生存极差。
- 多因素分析中仅CR和MRD状态对PFS和OS有独立预后价值。
核心结论
- 深度且持续的MRD阴性CR是最相关的预后因素,应考虑作为接受CAR-T细胞和TCE治疗的RRMM患者的治疗终点。
研究设计与样本
- 分析201例在临床试验中接受CAR-T细胞和T细胞衔接器(TCE)治疗的复发/难治性多发性骨髓瘤(RRMM)患者,使用二代流式分析MRD动态。
主要发现
- 达到10⁻⁶ MRD阴性与进展和/或死亡风险降低89%相关。
- 持续MRD阴性患者较短暂MRD阴性患者生存结局改善,持续MRD阳性患者生存结局极差。
- 意向治疗人群中,CAR-T细胞治疗者的MRD阴性率高于TCE治疗者。
- 在达到MRD阴性的患者中,按CAR-T细胞 vs TCE分层,生存结局无差异。
- 多因素分析(包括既往治疗线数、国际分期系统、细胞遗传学风险、髓外疾病和T细胞重定向免疫治疗类型)中,仅CR和MRD状态对PFS和OS显示独立预后价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Achieving MRD negativity at 10-6 was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent-to-treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when stratified according to treatment with CAR T cells versus TCE. In multivariate analysis including the number of prior lines of treatment, International Staging System, cytogenetic risk, extramedullary disease and type of T-cell redirecting immunotherapy, only the complete remission (CR) and MRD statuses showed independent prognostic value for progression-free and overall survival. In conclusion, our study shows that deep and sustained MRD negative CR is the most relevant prognostic factor and should be considered as the treatment endpoint in RRMM patients treated with CAR T cells and TCE.
引用
- Zabaleta A, Puig N, Cedena MT, et al. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. Am J Hematol. 2024. PMID: 39548827. doi:10.1002/ajh.27526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。